Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science
Episurf Medical (Nasdaq: EPIS B) will attend Redeye Theme Event: Commercialization in Life Science which is held on March 20th, 2025. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 12-minute pitch followed by an 8-minute Q&A.
The presentation will be streamed live at 10:10 CET at: https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2 and will also be made available afterwards on our website www.episurf.com.
Location: Redeye, Mäster Samuelsgatan 42, Stockholm.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on 19 March 2025.
Tags: